Tools & Techniques

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Precision for pancreatic cancer</h1><h2 class="title-bottom webtitle">How new tumor profiling methods could bring precision to pancreatic cancer</h2><div class="byline">Allison Johnson, Staff Writer</div><div class="date"></div></div></div></div>

Cold Spring Harbor Laboratory

Dana-Farber Cancer Institute

Pancreatic Cancer Action Network

Strata Oncology Inc.

Pancreatic cancer

Brian Wolpin

Dan Rhodes

Herve Tiriac

Victoria Manax

BRAF

Breast cancer 1 early onset (BRCA1)

Breast cancer 2 early onset (BRCA2)

Cyclin dependent kinase inhibitor 2A (CDKN2A) (INK4a) (ARF) (p16INK4a)

K-Ras (KRAS)

MAP kinase kinase 1 (MAP2K1) (MEK1)

Neuregulin 1 (NRG1) (HRG1)

Poly(ADP-ribose) polymerase (PARP)

Precision for pancreatic cancer

Two studies in  make the case for bringing personalized medicine to pancreatic cancer, even if most patients have KRAS mutations.

How new tumor profiling methods could bring precision to pancreatic cancer

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>